Elicio Therapeutics, Inc. (ELTX): Capital Expenditures
$16.0K
Year ended 2025-12-31
-71.0%
3-year compound annual growth
-17.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.0K | -81.6% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $87.0K | +31.8% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $66.0K | -89.9% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $654.0K | +71.2% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $382.0K | +831.7% | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | $41.0K | n/a | 2022-03-30, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $16.0K | -81.6% |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $50.0K | -77.7% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $16.0K | -92.8% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $346.0K | +81.2% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $28.5K | +762.8% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $0 | -100.0% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $76.1K | +31.4% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $110.8K | n/m |
| Immunic, Inc. (IMUX) | 2025-12-31 | $161.0K | -39.0% |
Compare ELTX, BYSI, CASIF, INBP side by side · Screen every company in Pharmaceutical Preparations ↗